These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 19293048)
1. What a strange thing it is to live. García Jordá E Clin Transl Oncol; 2009 Mar; 11(3):123-5. PubMed ID: 19293048 [No Abstract] [Full Text] [Related]
2. [Centralized treatment of rare types of cancer]. Schem BC Tidsskr Nor Laegeforen; 2002 Sep; 122(21):2088. PubMed ID: 12555641 [No Abstract] [Full Text] [Related]
3. Do we need randomised trials for rare cancers? Prasad V; Oseran A Eur J Cancer; 2015 Jul; 51(11):1355-7. PubMed ID: 25963018 [No Abstract] [Full Text] [Related]
4. International rare cancers initiative. Keat N; Law K; Seymour M; Welch J; Trimble T; Lascombe D; Negrouk A Lancet Oncol; 2013 Feb; 14(2):109-10. PubMed ID: 23369681 [No Abstract] [Full Text] [Related]
5. [Rare tumors: the need for special centers]. Massard C Bull Cancer; 2014 Feb; 101(2):115. PubMed ID: 25813683 [No Abstract] [Full Text] [Related]
6. "People with rare cancers get a raw deal in research and care". Newlands J Nurs Times; 2012 Feb 7-13; 108(6):11. PubMed ID: 22720483 [No Abstract] [Full Text] [Related]
7. Rare cancers: A network for better care. Sandrucci S; Gatta G Eur J Surg Oncol; 2019 Jan; 45(1):1-2. PubMed ID: 30041942 [No Abstract] [Full Text] [Related]
8. Rethinking the nonprofit foundation: an emerging niche in the rare disease ecosystem. Bakker AC; La Rosa S EMBO Mol Med; 2017 Sep; 9(9):1179-1182. PubMed ID: 28743783 [TBL] [Abstract][Full Text] [Related]
9. Strategy for randomised clinical trials in rare cancers. Tan SB; Dear KB; Bruzzi P; Machin D BMJ; 2003 Jul; 327(7405):47-9. PubMed ID: 12842959 [TBL] [Abstract][Full Text] [Related]
10. Should clinical trials be approached differently for rare cancers? Olver I Future Oncol; 2016 May; 12(10):1207-9. PubMed ID: 26939845 [No Abstract] [Full Text] [Related]
11. Specialized teams or specialist networks for rare cancers? Sandrucci S; Gatta G; Trama A; Dei Tos AP; Casali PG Eur J Surg Oncol; 2015 Sep; 41(9):1115-7. PubMed ID: 25936223 [No Abstract] [Full Text] [Related]
13. The founding of the European Cooperative Study Group on Pediatric Rare Tumors--EXPeRT. Ferrari A; Schneider DT; Bisogno G; Expert Rev Anticancer Ther; 2013 Jan; 13(1):1-3. PubMed ID: 23259419 [No Abstract] [Full Text] [Related]
14. A quarter of patients with rarer cancers see GPs several times before referral. Mayor S BMJ; 2016 Feb; 352():i1198. PubMed ID: 26929277 [No Abstract] [Full Text] [Related]
15. Editorial: Special issue on rare cancers. Sandler A; Reilly K; Widemann B Curr Probl Cancer; 2021 Aug; 45(4):100774. PubMed ID: 34304884 [No Abstract] [Full Text] [Related]
16. The evolving role of patient advocates in rare cancers: opportunities and challenges. Gonzato O; Gronchi A Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):1-3. PubMed ID: 30227750 [No Abstract] [Full Text] [Related]
17. The promise and challenges of rare cancer research. Komatsubara KM; Carvajal RD Lancet Oncol; 2016 Feb; 17(2):136-138. PubMed ID: 26868336 [No Abstract] [Full Text] [Related]
18. Rare cancers: the greatest inequality in cancer research and oncology treatment. Alvi MA; Wilson RH; Salto-Tellez M Br J Cancer; 2017 Oct; 117(9):1255-1257. PubMed ID: 28934760 [No Abstract] [Full Text] [Related]
19. Collaboration is key to treating uncommon cancers: scientists and patients champion research in these rare diseases. Printz C Cancer; 2010 Jun; 116(12):2847-9. PubMed ID: 20564387 [No Abstract] [Full Text] [Related]
20. To make progress in rare cancers, patients must lead the way. Dockser Marcus A J Clin Oncol; 2009 Jun; 27(16):2575-7. PubMed ID: 19414666 [No Abstract] [Full Text] [Related] [Next] [New Search]